BioNTech SE

BioNTech SE

Yahoo Finance • yesterday

BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

Quick Read BioNTech tumbled 8% and Moderna dropped 6% after BioNTech scrapped its colorectal cancer vaccine trial, crossing a futility boundary first flagged in October 2025. SPY held flat while Pfizer barely flinched, isolating the sell-... Full story

Yahoo Finance • 2 days ago

BioNTech (BNTX) Rallied on Moderna’s Win. Does a Competitor’s Success Validate its Oncology Pipeline?

BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy. Moderna and Merck said intismeran, combined with Keytruda, significantly improved recurrence-free and dis... Full story

Yahoo Finance • 2 days ago

Pfizer, BioNTech win approval for updated COVID-19 shot

[Covid-19 Vaccine] carmengabriela * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and BioNTech's (BNTX [https://seekingalpha.com/symbol/BNTX]) mRNA COVID-19 vaccine, COMIRNATY XFG, was approved by the US FDA for the 2026-27 season.... Full story

Yahoo Finance • 3 days ago

Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

Quick Read Moderna shed 7% of Tuesday's 14% Wolfe Research upgrade rally, while BioNTech's 2% dip confirms the selloff is Moderna-specific. IBB barely moved while Moderna's $59 billion cap prices in Merck's unapproved intismeran program a... Full story

Yahoo Finance • 3 days ago

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

MarketNewsUpdates.com A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where c... Full story

Yahoo Finance • 4 days ago

Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?

Quick Read Moderna surged 11% while BioNTech gained just 2% on no catalyst, with MRNA's Reddit sentiment score of 88 flagging crowded retail positioning over fundamentals. BioNTech trails XBI's 3% session gain and its 35% YTD return, whil... Full story

Yahoo Finance • 4 days ago

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

Quick Read MRK and MRNA's intismeran autogene beat Keytruda alone on recurrence-free survival in Phase 3 melanoma, though no specific efficacy numbers have been released yet. BNTX surged 21% on read-across excitement, while ILMN rose 16%... Full story

Yahoo Finance • 5 days ago

Should You Buy Moderna Stock Following Its Cancer Breakthrough?

Moderna MRNA has gained renewed investor attention after its personalized mRNA-based cancer therapy delivered positive results in a late-stage study. The therapy has been developed in collaboration with Merck MRK. Moderna's Cancer Therapy... Full story

Yahoo Finance • 5 days ago

Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips

Quick Read MRNA drops 7% to $135 after a 392% YTD surge, as traders book profits with no new negative catalysts driving the decline. Partner MRK gained 47% YTD on Keytruda's label expansion potential, while BNTX trails at 22% amid a slowe... Full story

Yahoo Finance • 5 days ago

A cancer vaccine years in the making just proved itself

On August 19, Merck (MRK) said its personalized cancer vaccine had proved effective in a large, late-stage melanoma study, and Wall Street responded fast. Merck shares closed up about 12.5% that day, one of the biggest single-day moves th... Full story

Yahoo Finance • 8 days ago

Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers Continue Reading... Full story

Yahoo Finance • 8 days ago

Why Moderna’s mRNA Cancer Drug Hype Has Gone Too Far

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers Continue Reading... Full story

Yahoo Finance • 9 days ago

Moderna's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?

Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run. Continue Reading... Full story

Yahoo Finance • 9 days ago

Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips

Quick Read Moderna (MRNA) dropped 20% Thursday, reversing part of Wednesday's 177% surge, while BioNTech (BNTX) fell 4% on diminishing read-across enthusiasm. The complete intismeran dataset, due at ESMO in Madrid from October 23 to 27, w... Full story

Yahoo Finance • 10 days ago

Moderna shares double as cancer vaccine data rekindles investor hopes

By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer ‌therapy developed wi... Full story

Yahoo Finance • 10 days ago

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Quick Read Moderna surges 93% and Merck gains 7% after their cancer combo becomes the first personalized mRNA therapy to clear a Phase 3 trial. BioNTech, the other major mRNA cancer developer, rose just 1% while the broad XLV ETF gained o... Full story

Yahoo Finance • 17 days ago

U.K. regulator reaffirms safety of childhood vaccination

[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed... Full story

Yahoo Finance • 18 days ago

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized... Full story

Yahoo Finance • 25 days ago

BioNTech anticipates €1.6B-€1.9B 2026 revenue while advancing oncology catalysts into late 2026

Earnings Call Insights: BioNTech (BNTX) Q2 2026 MANAGEMENT VIEW * BioNTech framed its leadership transition as tied to commercialization scale, with (Chairman Helmut Jeggle) saying, "Guido Oelkers will take office as CEO as of February... Full story

Yahoo Finance • 25 days ago

Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading... Full story